| EXAMINATION | - Anonymous, "NCT00485303 on 2007_06_13: ClinicalTrials.gov Archive", (20070613), pages 1 - 3, URL: https://clinicaltrials.gov/archive/NCT00485303/2007_06_13, (20170731), XP055394875 |
| EXAMINATION | - Anonymous, "Summary of product characteristics for Zytiga 250 mg tablets", Summary of product characteristics for Zytiga 250 mg tablets, (20140121), XP055750423 |
| EXAMINATION | - DANILA DANIEL C ET AL, "Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 MAR 2010, (20100320), vol. 28, no. 9, ISSN 1527-7755, pages 1496 - 1501 |
| EXAMINATION | - Garnick M B, Motta C, "Androgen deprivation therapy:the future 93", Garnick M B, Motta C, Kirby R S, Partin A W, Feneley M, Parsons J K, Prostatce Cancer - Principles and Practice, CRC Press Taylor & Francis Group, (20060113), pages 915 - 928, ISBN 9781841844589 |
| EXAMINATION | - GOLDSMITH O ET AL, "Hypogonadism and mineralocorticoid excess. the 17-hydroxylase deficiency syndrome", NEW ENGLAND JOURNAL OF MEDICINE (PRINT) 1967, (1967), vol. 277, no. 13, ISSN 0028-4793, page 614 |
| EXAMINATION | - LAM J S ET AL, "Secondary Hormonal Therapy for Advanced Prostate Cancer", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 175, no. 1, doi:10.1016/S0022-5347(05)00034-0, ISSN 0022-5347, (20060101), pages 27 - 34, (20060101), XP024990140 |
| EXAMINATION | - FAKIH MARWAN ET AL, "Glucocorticoids and treatment of prostate cancer: A preclinical and clinical review", UROLOGY, BELLE MEAD, NJ, US, (20021001), vol. 60, no. 4, doi:10.1016/S0090-4295(02)01741-7, ISSN 0090-4295, pages 553 - 561, XP002495992 |
| EXAMINATION | - RUTZ H P, "Effects of corticosteroid use on treatment of solid tumours", THE LA, THE LANCET PUBLISHING GROUP, GB, (20021214), vol. 360, no. 9349, doi:10.1016/S0140-6736(02)11922-2, ISSN 0140-6736, pages 1969 - 1970, XP004795228 |
| EXAMINATION | - HERR I ET AL, "Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 5, doi:10.1016/S1470-2045(06)70694-5, ISSN 1470-2045, (20060501), pages 425 - 430, (20060501), XP028057866 |
| EXAMINATION | - ATTARD G ET AL, "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer", BJU INTERNATIONAL, BLACKWELL SCIENCE, OXFORD, GB, (20050101), vol. 96, doi:10.1111/J.1464-410X.2005.05821.X, ISSN 1464-4096, pages 1241 - 1246, XP002497670 |
| OPPOSITION | - "Androgen deprivation therapy: the future", Camille Motta; Marc B Garnick, Prostate Cancer: Principles and Practice, CRC Press, (20060100), pages 919 - 928, XP055458243 |
| OPPOSITION | - Anonymous, "A phase II open label study of CB7630 (abiraterone acetate) and prednisone in patients with advanced prostate cancer who have failed androgen deprivation and docetaxel-based chemotherapy", clinicaltrials.gov, (20070611), pages 1 - 3, URL: https://clinicaltrials.gov/archive/NCT00485303/ 2007 06 11, XP055892142 |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00485303 Clinical Study of Abiraterone Acetate and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed An and Docetaxel-Based Chemotherapy ", ClinicalTrials.org archive, (20070612), pages 1 - 6, ClinicalTrials.org archive , URL: https://clinicaltrials.gov/ct2/history/NCT00485303?A=2&B=2&C=merged#StudyPageTop, (20220217), XP055893197 |
| OPPOSITION | - Anonymous, "History of changes for Study: NCT00485303 - Clinical Study of Abiraterone Acetate and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy", ClinicalTrials.gov Archive, (20070608), pages 1 - 4, ClinicalTrials.gov Archive, (20220202), XP055886715 |
| OPPOSITION | - Anonymous, "NCT00485303 on 2007_06_13: ClinicalTrials.gov Archive", (20070613), pages 1 - 3, URL: https://clinicaltrials.gov/archive/NCT00485303/2007_06_13, (20170731), XP055394875 |
| OPPOSITION | - Anonymous, "Putting prednisone in perspective", Janssen Biotech, Inc., (20150301), pages 1 - 4, XP055893179 |
| OPPOSITION | - Anonymous, "View on NCT00485303 on 2007_06_11", ClinicalTrials.gov Archive, (20070611), pages 1 - 3, ClinicalTrials.gov Archive, URL: https://clinicaltrials.gov/ct2/archive/NCT00485303, (20211007), XP055848713 |
| OPPOSITION | - Anonymous, "View on NCT00485303 on 2007_06_11", ClinicalTrials.gov Archive, (20070611), pages 1 - 3, URL: https://clinicaltrials.gov/ct2/archive/NCT00485303, XP055848713 |
| OPPOSITION | - Anonymous, "View on NCT00485303 on 2007_06_11", NCT00485303, (20070611), pages 1 - 3, XP055848713 |
| OPPOSITION | - ANONYMOUS, "View on NCT00485303 on 2007_06_11", NCT00485303 on clinicaltrials.gov, (20070611), pages 1 - 3, XP055848713 |
| OPPOSITION | - A. O'DONNELL et al., "Hormonal impact of the 17[alpha]-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer", British Journal of Cancer, (20040000), vol. 90, no. 12, pages 2317 - 2325, XP002464868 |
| OPPOSITION | - A. O' DONNELL et al., "Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer", British Journal of Cancer, (20040000), vol. 90, pages 2316 - 2325, XP002464868 |
| OPPOSITION | - Attard G, Et Al, "Improving the outcome of patients with castration-resistant prostate cancer through rational drug development", British Journal of Cancer, (20060101), vol. 95, pages 767 - 774, XP055886378 |
| OPPOSITION | - Attard G, Et Al, "Improving the outcome of patients with castration-resistant prostate cancer through rational drug development", British Journal of Cancer, (20060101), vol. 95, pages 767 - 774, XP055886663 |
| OPPOSITION | - ATTARD G, YAP A, REID A H, PARKER C, BARRETT M, RAYNAUD F, DOWSETT M, DEARNALEY D, LEE G, DE BONO J S, "Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor", Journal of Clinical Oncology, US , (20070601), vol. 25, no. 18Suppl., ISSN 0732-183X, pages 1 - 2, XP002497668 |
| OPPOSITION | - Auchus Richard J, "The Genetics, Pathophysiology, and Management of Human Deficiencies of P450c17", Endocrinology and Metabolism Clinics of North America, (20010301), vol. 30, no. 1, pages 101 - 119, XP055884148 |
| OPPOSITION | - BARRIE et al., "Pharmacology of Novel Steroidal Inhibitors of Cytochrome P450 17.alpha (17.alpha.-Hydroxylase/C17-20 Lyase)", Journal of Steroid Biochemistry & Molecular Biology, (19940000), vol. 50, no. 5-6, pages 267 - 273, XP002581259 |
| OPPOSITION | - BARRIE SE et al., "Pharmacology of Novel Steroidal Inhibitors of Cytochrome P450 17.alpha (17.alpha.-Hydroxylase/C17-20 Lyase)", Journal of Steroid Biochemistry & Molecular Biology,, (19940900), vol. 50, no. 5-6, pages 267 - 273, XP002581259 |
| OPPOSITION | - BARRIE SE et al., "Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase", J Steroid Biochem Mal Biol., (19940900), vol. 50, no. 5-6, pages 267 - 73, XP002581259 |
| OPPOSITION | - Camille Motta, Marc B Garnick, "Androgen deprivation therapy: the future", Prostate Cancer: Principles and Practice, CRC Press , (20060101), page 17 pp., ISBN 978-1-84184-458-9, XP055458243 |
| OPPOSITION | - Camille Motta, Marc B Garnick, "Androgen deprivation therapy: the future", Prostate Cancer: Principles and Practice, CRC Press, (20060101), page 17 pp., ISBN 978-1-84184-458-9, XP055458243 |
| OPPOSITION | - "Chapter 45/ Molecular Endocrinology of the Testis", Marschall S. Runge, Cam Patterson, Victor A. Mckusick, Principles of Molecular Medicine 2nd Edition, Humana Press, (20060000), pages 482 - 484, XP055848742 |
| OPPOSITION | - "Chapter 77- Hormones and Hormone Antagonists", Alfonso R Gennaro, Et Al.,, Remington THE SCIENCE AND PRACTICE OF PHARMACY 20th Edition, Lippincott Williams & Wilkins, (20000000), pages 1363 - 1370, XP055848726 |
| OPPOSITION | - Cougar Biotechnology, Inc., "Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting ", Internet Archive Wayback Machine, (20070704), pages 1 - 2, Internet Archive Wayback Machine , URL: https://web.archive.org/web/20070704051015/http://www.cougarbiotechnology.com/pr060407.html, (20220215), XP055892128 |
| OPPOSITION | - C. Wang, R. T. T. Yeung, J. P. Coghlan, C. J. Oddie, B. A. Scoggins And J. R. Stockigt, "Hypertension Due to 17alpha-Hydroxylase Deficiency", Australian and New Zealand Journal of Medicine, (19780601), vol. 8, no. 3, pages 295 - 299, XP055893188 |
| OPPOSITION | - D Osoba et al, "Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone", Journal of Clinical Oncology, (19990601), vol. 17, no. 6, pages 1654 - 1663, XP055848730 |
| OPPOSITION | - D Osoba, I F Tannock, D S Ernst, A J Neville, "Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone", J Clin Oncol, (19990600), vol. 17, no. 6, pages 1654 - 1663, XP055848730 |
| OPPOSITION | - D Osoba, I F Tannock, D S Ernst, A J Neville, "Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone", Journal of Clinical Oncology, (19990601), vol. 17, no. 6, pages 1654 - 1663, XP055848730 |
| OPPOSITION | - E David Crawford, Neal D Shore, Daniel P Petrylak , Celestia S Higano, Charles J Ryan, "Abiraterone acetate and prednisone in chemotherapy-naive prostate cancer patients: rationale, evidence and clinical utility", Therapeutic Advances in Medical Oncology, (20170500), vol. 9, no. 5, pages 319 - 333, XP055848721 |
| OPPOSITION | - E. P. GELMANN, "Molecular Biology of the Androgen Receptor", JOURNAL OF CLINICAL ONCOLOGY, (20020701), vol. 20, no. 13, pages 3001 - 3015, XP002653325 |
| OPPOSITION | - Ergun-Longmire, Et Al., "Two Novel Mutations in a Patient with 17a-Hydroxylase Enzyme Defficiency", The Journal of Clinical Endocrinology & Metabolism, (20060718), vol. 91, no. 10, pages 4179 - 4182, XP055892455 |
| OPPOSITION | - ERGUN-LONGMIRE et al., "Two Novel Mutations in a Patient with 17a-Hydroxylase Enzyme Defficiency", The Journal of Clinical Endocrinology & Metabolism, (20060718), vol. 91, no. 10, pages 4179 - 4182, XP055892455 |
| OPPOSITION | - European Medicines Agency, "Assessment report for Zytiga (abiraterone). Procedure No.: EMEA/H/C/002321. Pages 1, 2, 8-10.", (20110721), pages 1 - 5, URL: www.ema.europa.eu, (20121102), XP002686401 |
| OPPOSITION | - Fossa S D, Et Al, "Flutamide Versus Prednisone in Patients with Protate Cancer Symptomatically Progressing after Androgen-Ablative Therapy: A Phase III Study of the European Organization for Research and Treatment of Cancer Genitourinary Group", Journal of Clinical Oncology, (20010101), vol. 19, no. 1, pages 62 - 71, XP055879265 |
| OPPOSITION | - Gerber G S; Chodak G W, "Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer", Journal of Urology, (19900000), vol. 144, no. 5, pages 1177 - 1179, XP008151701 |
| OPPOSITION | - Gerber G S; Chodak G W, "Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer", Journal of Urology, (19901100), vol. 144, no. 5, pages 1177 - 1179, XP008151701 |
| OPPOSITION | - Gerber G S; Chodak G W, "Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer", Journal of Urology, BALTIMORE, MD, US , (19900101), vol. 144, no. 5, ISSN 0022-5347, pages 1177 - 1179, XP008151701 |
| OPPOSITION | - Gerber G S; Chodak G W, "Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer", Journal of Urology, Lippincott Williams & Wilkins, BALTIMORE, MD, US, BALTIMORE, MD, US , (19900101), vol. 144, no. 5, ISSN 0022-5347, pages 1177 - 1179, XP008151701 |
| OPPOSITION | - GERBER, G.S. et al., J. Urology, (19900000), vol. 144, pages 1177 - 1179, XP008151701 |
| OPPOSITION | - GERBER, G.S. et al., "Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer", Journal of Urology, (19900000), vol. 144, no. 5, pages 1177 - 1179, XP008151701 |
| OPPOSITION | - GERBER G S et al., "Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer", Journal of Urology, (19900101), vol. 144, no. 5, page 1177, XP008151701 |
| OPPOSITION | - Heng Daniel Y.C., Et Al, "Prednisone monotherapy in asymptomatic hormone refractory prostate cancer", The Canadian Journal of Urology, (20061201), vol. 13, no. 6, pages 3335 - 3339, XP055884140 |
| OPPOSITION | - Ian Tannock et al, "Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response", Journal of Clinical Oncology, (19890501), vol. 7, no. 5, pages 590 - 597, XP055848733 |
| OPPOSITION | - Ian Tannock, Mary Gospodarowicz, William Meakin, Tony Panzarella, Lesley Stewart, and Walter Rider, "Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response", Journal of Clinical Oncology, (19890500), vol. 7, no. 5, pages 590 - 597, XP055848733 |
| OPPOSITION | - Ian Tannock, Mary Gospodarowicz, William Meakin, Tony Panzarella, Lesley Stewart, And Walter Rider, "Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response", Journal of Clinical Oncology, (19890501), vol. 7, no. 5, pages 590 - 597, XP055848733 |
| OPPOSITION | - Juruena Mario F, Cleare Anthony J, Pariante Carmine M, "The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression", Revista brasileira de psiquiatria, Publ. Solutions, BR, BR , (20040901), vol. 26, no. 3, ISSN 1516-4446, pages 189 - 201, XP055892096 |
| OPPOSITION | - KIRBY, R.S. et al., "Androgen deprivation therapy: the future", Prostate cancer, principles and practice, (20060100), pages 915 - 928, XP055892145 |
| OPPOSITION | - Kirby R. S., Et Al., "Androgen deprivation therapy: the future", Prostate cancer, principles and practice, (20060101), pages 915 - 928, XP055892145 |
| OPPOSITION | - MADAN, R.A. et al., "Abiraterone Cougar Biotechnology", IDrugs, (20060100), vol. 9, no. 1, pages 49 - 55, XP008087480 |
| OPPOSITION | - MADAN RAVI A; ARLEN PHILIP M, "Abiraterone Cougar Biotechnology", IDrugs: The Investigational Drugs Journal, (20060000), vol. 9, no. 1, pages 49 - 55, XP008087480 |
| OPPOSITION | - MADAN RAVI A, ARLEN PHILIP M, "Abiraterone Cougar Biotechnology", IDrugs: The Investigational Drugs Journal, Current Drugs Ltd., GB, GB , (20060101), vol. 9, no. 1, ISSN 1369-7056, pages 49 - 55, XP008087480 |
| OPPOSITION | - MADAN RAVI A, ARLEN PHILIP M, "Abiraterone Cougar Biotechnology", IDrugs: The Investigational Drugs Journal, Current Drugs Ltd., GB, GB, (20060101), vol. 9, no. 1, ISSN 1369-7056, pages 49 - 55, XP008087480 |
| OPPOSITION | - Marc B Garnick, Camille Motta, "Androgen deprivation therapy: the future", Marc B Garnick, Camille Motta, Roger S Kirby, Alan W Partin, Mark R Feneley, J Kellogg Parsons, Prostate Cancer - Principles and Practice, Taylor & Francis, (20060000), pages 915 - 928, XP055752081 |
| OPPOSITION | - Marc B. Garnick, Camille Motta, "Chapter 93 - Androgen deprivation therapy: the future", Prostate Cancer, Principles and Practice, (20060101), pages 915 - 928, XP055752081 |
| OPPOSITION | - O'DONNELL A et al., "Hormonal impact of the 17[alpha]-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer", British Journal of Cancer,, (20040614), vol. 90, no. 12, pages 2317 - 2325, XP002464868 |
| OPPOSITION | - O'DONNELL A, ET AL, "Hormonal impact of the 17[alpha]-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer", British Journal of Cancer, London, (20040614), vol. 90, no. 12, ISSN 0007-0920, pages 2317 - 2325, XP002464868 |
| OPPOSITION | - O'DONNELL A, ET AL, "Hormonal impact of the 17[alpha]-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer", British Journal of Cancer,, London, (20040614), vol. 90, no. 12, ISSN 0007-0920, pages 2317 - 2325, XP002464868 |
| OPPOSITION | - O'DONNELL A, ET AL, "Hormonal impact of the 17[alpha]-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer", British Journal of Cancer, Nature Publishing Group, GB, GB, (20040614), vol. 90, no. 12, ISSN 0007-0920, pages 2317 - 2325, XP002464868 |
| OPPOSITION | - O'DONNELL A, ET AL, "Hormonal impact of the 17[alpha]-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer", British Journal of Cancer, Nature Publishing Group UK, London, London, (20040614), vol. 90, no. 12, ISSN 0007-0920, pages 2317 - 2325, XP002464868 |
| OPPOSITION | - O'DONNELL et al., "Hormonal impact of the 17alpha-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer", British Journal of Cancer, (20040000), vol. 90, pages 2317 - 2325, XP002464868 |
| OPPOSITION | - Oliver Goldsmith, David H. Solomon And Richard Horton, "Hypogonadism and mineralocorticoid excess. The 17-hydroxylase deficiency syndrome", The New England Journal of Medicine, (19670928), vol. 277, no. 13, pages 673 - 677, XP055750805 |
| OPPOSITION | - Osoba D; Tannock I F; Ernst D S; Neville A J, "Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone", Journal of Clinical Oncology, (19990000), vol. 17, no. 6, pages 1654 - 1663, XP055848730 |
| OPPOSITION | - Patrick N. Friel, Thomas Alexander, Jonathan V. Wright, "Suppression of adrenal function by low- dose prednisone: assessment with 24-hour urinary steroid hormone profiles -a review of five cases", Alternative Medicine Review, (20060300), vol. 11, no. 1, pages 40 - 46, XP055848740 |
| OPPOSITION | - Patrick N. Friel, Thomas Alexander, Jonathan V. Wright, "Suppression of adrenal function by low- dose prednisone: assessment with 24-hour urinary steroid hormone profiles - a review of five cases", Alternative Medicine Review, (20060301), vol. 11, no. 1, pages 40 - 46, XP055848740 |
| OPPOSITION | - "PRINCIPLES AND PRACTICE OF ENDOCRINOLOGY AND METABOLISM 3. EDITION /PASSAGE/", Kenneth L. Becker, Et Al.,, PRINCIPLES AND PRACTICE OF ENDOCRINOLOGY AND METABOLISM 3. EDITION, LIPPINCOTT WILLIAMS & WILKINS, (20010101), page 3PP, 1197, XP055893034 |
| OPPOSITION | - "Prinzipien der Biochemie, 2. Auflage /Passage/", Albert L Lehninger, David L Nelson; Michael M Cox, Prinzipien der Biochemie, 2. Auflage, SPEKTRUM AKADEMISCHE VERLAG GMBH, BERLIN, (19980101), pages 2pp, 297 - 780, XP055892107 |
| OPPOSITION | - Robert C, Wilson, Maria I. New, "37 Congenital Adrenal Hyperplasia", Robert C, Wilson, Maria I. New, Marschall S. Runge, Cam Patterson, Victor A. McKusick, Principles of Molecular Medicine SECOND EDITION, Humana Press, (20060101), pages 365-367, 482 - 484, XP055893161 |
| OPPOSITION | - S. E. BARRIE ET AL, "Pharmacology of Novel Steroidal Inhibitors of Cytochrome P450 17.alpha (17.alpha.-Hydroxylase/C17-20 Lyase)", Journal of Steroid Biochemistry & Molecular Biology, ELSEVIER SCIENCE LTD., OXFORD., GB, GB , (19940901), vol. 50, no. 5-6, ISSN 0960-0760, pages 267 - 273, XP002581259 |
| OPPOSITION | - TANNOCK et al., "Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response", Journal of Clinical Oncology, (19890500), vol. 7, no. 5, pages 590 - 597, XP055848733 |
| OPPOSITION | - "View on NCT00485303 on 2007_06_11", ClinicalTrials.gov Archive, (20070611), pages 1 - 3, URL: https://clinicaltrials.gov/ct2/archive/NCT00485303, XP055848713 |
| OPPOSITION | - Steketee Karine, Timmerman Leon, Ziel-Van Der Made Angelique C.J., Doesburg Paul, Brinkmann Albert O., Trapman Jan, "Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer", International Journal of Cancer, (20020720), vol. 100, no. 3, pages 309 - 317, XP055848768 |
| OPPOSITION | - Sills I N; MacGillivray M H; Amrhein J A; Migeon C J; Peterson R E, "17@a-Hydroxylase deficiency in a genetic male and female sibling pair", INTERNATIONAL JOURNAL OF GYNECOLOGY AND OBSTETRICS, (19810000), vol. 19, no. 6, pages 473 - 479, XP026248373 |
| OPPOSITION | - Cameron M Armstrong; Allen C Gao, "Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer", Asian Journal of Urology, (20161000), vol. 3, no. 4, doi:10.1016/j.ajur.2016.08.001, pages 185 - 194, XP055392203 |
| OPPOSITION | - Cameron M. Armstrong, Allen C. Gao, "Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer", Asian Journal of Urology, (20161001), vol. 3, no. 4, doi:10.1016/j.ajur.2016.08.001, ISSN 2214-3882, pages 185 - 194, XP055392203 |
| OPPOSITION | - FOSSA et al., "Weekly Docetaxel and Prednisolone versus Prednisone Alone in Androgen- Independent Prostate Cancer: A Randomized Phase II Stud y", European Urology, (20071121), vol. 52, no. 6, pages 1691 - 1699, XP022338021 |
| OPPOSITION | - Fossa, S.D.et al, "Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study", European Urology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL, (20071108), vol. 52, no. 6, doi:10.1016/j.eururo.2007.01.104, ISSN 0302-2838, pages 1691 - 1699, XP022338021 |
| OPPOSITION | - FOSSA, S.D. et al., "Weekly docetaxel and prednisolone versus prednisone alone in androgen-independent prostate cancer: a randomized phase II study", European Urology, (20070000), vol. 52, no. 6, pages 1691 - 1699, XP022338021 |
| OPPOSITION | - Fossa, S.D. Jacobsen, A.B. Ginman, C. Jacobsen, I.N. Overn, S. Iversen, J.R. Urnes, T. Dahl, A.A. Veenstra, M. Sandstad, B., "Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study", European Urology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20071108), vol. 52, no. 6, doi:10.1016/j.eururo.2007.01.104, ISSN 0302-2838, pages 1691 - 1699, XP022338021 |
| OPPOSITION | - LAM, J.S. et al., "Secondary hormonal therapy for advanced prostate cancer", The Journal of Urology, (20060100), vol. 175, doi:10.1016/S0022-5347(05)00034-0, pages 27 - 34, XP024990140 |
| OPPOSITION | - Lam J S; Leppert J T; Vemulapalli S N; Shvarts O; Belldegrun A S, "Secondary hormonal therapy for advanced prostate cancer", Journal of Urology, (20060100), vol. 175, no. 1, doi:10.1016/S0022-5347(05)00034-0, pages 27 - 34, XP024990140 |
| OPPOSITION | - Lam, J.S. Leppert, J.T. Vemulapalli, S.N. Shvarts, O. Belldegrun, A.S., "Secondary Hormonal Therapy for Advanced Prostate Cancer", Journal of Urology, BALTIMORE, MD, US , (20060101), vol. 175, no. 1, doi:10.1016/S0022-5347(05)00034-0, ISSN 0022-5347, pages 27 - 34, XP005366788 |
| OPPOSITION | - Lam, J.S. Leppert, J.T. Vemulapalli, S.N. Shvarts, O. Belldegrun, A.S., "Secondary Hormonal Therapy for Advanced Prostate Cancer", Journal of Urology, Lippincott Williams & Wilkins, BALTIMORE, MD, US, BALTIMORE, MD, US , (20060101), vol. 175, no. 1, doi:10.1016/S0022-5347(05)00034-0, ISSN 0022-5347, pages 27 - 34, XP005366788 |
| OPPOSITION | - Lam, J.S. Leppert, J.T. Vemulapalli, S.N. Shvarts, O. Belldegrun, A.S., "Secondary Hormonal Therapy for Advanced Prostate Cancer", Journal of Urology, Lippincott Williams & Wilkins, BALTIMORE, MD, US, BALTIMORE, MD, US, (20060101), vol. 175, no. 1, doi:10.1016/S0022-5347(05)00034-0, ISSN 0022-5347, pages 27 - 34, XP005366788 |
| OPPOSITION | - Lam, J.S. ; Leppert, J.T. ; Vemulapalli, S.N. ; Shvarts, O. ; Belldegrun, A.S., "Secondary Hormonal Therapy for Advanced Prostate Cancer", Journal of Urology, Lippincott Williams & Wilkins, BALTIMORE, MD, US, BALTIMORE, MD, US , (20060101), vol. 175, no. 1, doi:10.1016/S0022-5347(05)00034-0, ISSN 0022-5347, pages 27 - 34, XP024990140 |
| OPPOSITION | - Lam J S; Leppert J T; Vemulapalli S N; Shvarts O; Belldegrun A S, "Secondary Hormonal Therapy for Advanced Prostate Cancer", The Journal of Urology, (20060100), vol. 175, pages 27 - 34, XP024990140 |
| OPPOSITION | - Lam; Leppert J S; Vemulapalli J T; Shvarts S N; Belldegrun O; A S, "Secondary Hormonal Therapy for Advanced Prostate Cancer", The Journal of Urology, (20060100), vol. 175, no. 1, pages 27 - 34, XP005366788 |
| OPPOSITION | - HARRIS et al., "Low Dose Ketoconazole with Replacement Doses of Hydrocortisone in Patients with Progressive Androgen Independent Prostate Cancer", Journal of Urology, (20020801), vol. 168, no. 2, doi:10.1016/S0022-5347(05)64675-7, pages 542 - 545, XP005540121 |
| OPPOSITION | - HARRIS et al., "Low Dose Ketoconazole With Replacement Doses of Hydrocortisone in Patients with Progressive Androgen Independent Prostate Cancer", Journal of Urology, (20020801), vol. 168, no. 2, doi:10.1016/S0022-5347(05)64675-7, pages 542 - 545, XP005540121 |
| OPPOSITION | - Harris, K.A. Weinberg, V. Bok, R.A. Kakefuda, M. Small, E.J., "Low Dose Ketoconazole With Replacement Doses of Hydrocortisone in Patients With Progressive Androgen Independent Prostate Cancer", Journal of Urology, Lippincott Williams & Wilkins, BALTIMORE, MD, US, BALTIMORE, MD, US , (20020801), vol. 168, no. 2, doi:10.1016/S0022-5347(05)64675-7, ISSN 0022-5347, pages 542 - 545, XP005383648 |
| OPPOSITION | - Harris; Weinberg K A; Bok V; Kakefuda R A; Small M; E J, "Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer", Journal of Urology, (20020000), vol. 168, no. 2, pages 542 - 545, XP005540121 |
| OPPOSITION | - Harris; Weinberg K A; Bok V; Kakefuda R A; Small M; E J, "Low Dose Ketoconazole With Replacement Doses of Hydrocortisone in Patients With Progressive Androgen Independent Prostate Cancer", Journal of Urology, (20020800), vol. 168, no. 2, pages 542 - 545, XP005540121 |
| OPPOSITION | - FAKIH et al., "Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review", Urology, (20020000), vol. 60, no. 4, doi:10.1016/S0090-4295(02)01741-7, pages 553 - 561, XP002495992 |
| OPPOSITION | - FAKIH MARWAN; JOHNSON CANDACE S; TRUMP DONALD L, "Glucocorticoids and treatment of prostate cancer: A preclinical and clinical review", Urology, (20020000), vol. 60, no. 4, pages 553 - 561, XP002495992 |
| OPPOSITION | - FAKIH MARWAN , JOHNSON CANDACE S, TRUMP DONALD L, "Glucocorticoids and treatment of prostate cancer: A preclinical and clinical review", UROLOGY., BELLE MEAD, NJ, US, US , (20021001), vol. 60, no. 4, doi:10.1016/S0090-4295(02)01741-7, ISSN 0090-4295, pages 553 - 561, XP002495992 |
| OPPOSITION | - FAKIH MARWAN , JOHNSON CANDACE S, TRUMP DONALD L, "Glucocorticoids and treatment of prostate cancer: A preclinical and clinical review", UROLOGY., BELLE MEAD, NJ, US, US, (20021001), vol. 60, no. 4, doi:10.1016/S0090-4295(02)01741-7, ISSN 0090-4295, pages 553 - 561, XP002495992 |
| OPPOSITION | - FAKIH MARWAN , JOHNSON CANDACE S, TRUMP DONALD L, "Glucocorticoids and treatment of prostate cancer: A preclinical and clinical review", UROLOGY, US , (20021001), vol. 60, no. 4, doi:10.1016/S0090-4295(02)01741-7, ISSN 0090-4295, pages 553 - 561, XP002495992 |
| OPPOSITION | - FAKIH, M. et al., "Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review", Urology, (20020000), vol. 60, no. 4, doi:10.1016/S0090-4295(02)01741-7, pages 553 - 561, XP002495992 |
| OPPOSITION | - FAKIH, M. et al., Urology, (20020000), vol. 60, pages 553 - 561, XP002495992 |
| OPPOSITION | - Sartor Oliver et al, "Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer", UROLOGY, US , (19980801), vol. 52, no. 2, doi:10.1016/S0090-4295(98)00149-6, ISSN 0090-4295, pages 252 - 256, XP055797370 |
| OPPOSITION | - Sartor Oliver et al, "Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer", UROLOGY., US , (19980801), vol. 52, no. 2, doi:10.1016/S0090-4295(98)00149-6, ISSN 0090-4295, pages 252 - 256, XP055797370 |
| OPPOSITION | - Sartor Oliver; Weinberger Maribeth; Moore Andrea; Li Ailing; Figg William D, "Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer", Urology, (19980800), vol. 52, no. 2, doi:10.1016/S0090-4295(98)00149-6, pages 252 - 256, XP055797370 |
| OPPOSITION | - Sartor Oliver, Weinberger Maribeth, Moore Andrea, Li Ailing, Figg William D, "Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer", UROLOGY., BELLE MEAD, NJ, US, US , (19980801), vol. 52, no. 2, doi:10.1016/S0090-4295(98)00149-6, ISSN 0090-4295, pages 252 - 256, XP055797370 |
| OPPOSITION | - Sartor Oliver, Weinberger Maribeth, Moore Andrea, Li Ailing, Figg William D, "Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer", UROLOGY, US , (19980801), vol. 52, no. 2, doi:10.1016/S0090-4295(98)00149-6, ISSN 0090-4295, pages 252 - 256, XP055797370 |
| OPPOSITION | - Sartor Oliver, Weinberger Maribeth, Moore Andrea, Li Ailing, Figg William D, "Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer", UROLOGY., US , (19980801), vol. 52, no. 2, doi:10.1016/S0090-4295(98)00149-6, ISSN 0090-4295, pages 252 - 256, XP055797370 |
| OPPOSITION | - H.P RUTZ, "Effects of corticosteroid use on treatment of solid tumours", The Lancet, (20021214), vol. 360, pages 1969 - 1970, XP004398794 |
| OPPOSITION | - RUTZ, H.P., "Effects of corticosteroid use on treatment of solid tumours", The Lancet, (20020000), vol. 360, doi:10.1016/S0140-6736(02)11922-2, pages 1969 - 1970, XP004795228 |
| OPPOSITION | - Rutz, H.P., "Effects of corticosteroid use on treatment of solid tumours", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20021214), vol. 360, no. 9349, doi:10.1016/S0140-6736(02)11922-2, ISSN 0140-6736, pages 1969 - 1970, XP004795228 |
| OPPOSITION | - HERR, I. et al., "Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastaseses", The Lancet Oncology, (20060507), doi:10.1016/S1470-2045(06)70694-5, pages 425 - 430, XP028057866 |
| OPPOSITION | - Herr I; Pfitzenmaier J, "Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases", The Lancet Oncology, (20060500), vol. 7, no. 5, doi:10.1016/S1470-2045(06)70694-5, pages 425 - 430, XP028057866 |
| OPPOSITION | - Herr, I. Pfitzenmaier, J., "Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases", The Lancet Oncology, AMSTERDAM, NL , (20060501), vol. 7, no. 5, doi:10.1016/S1470-2045(06)70694-5, ISSN 1470-2045, pages 425 - 430, XP005407764 |
| OPPOSITION | - Herr, I. Pfitzenmaier, J., "Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20060501), vol. 7, no. 5, doi:10.1016/S1470-2045(06)70694-5, ISSN 1470-2045, pages 425 - 430, XP005407764 |
| OPPOSITION | - Herr, I. ; Pfitzenmaier, J., "Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20060501), vol. 7, no. 5, doi:10.1016/S1470-2045(06)70694-5, ISSN 1470-2045, pages 425 - 430, XP028057866 |
| OPPOSITION | - I. HERR et al., "Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases", The Lancet Oncology, (20060507), vol. 7, no. 5, pages 425 - 430, XP005407764 |
| OPPOSITION | - I. HERR et al., The Lancet Oncology, (20060507), pages 425 - 430, XP005407764 |
| OPPOSITION | - POTTER GA et al., "Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer", J Med Chem., (19950623), vol. 38, no. 13, doi:10.1021/jm00013a022, pages 2463 - 2471, XP002302489 |
| OPPOSITION | - POTTER G A,ET AL, "Novel steroidal inhibitors of human cytochrome P450-17alpha (17-alpha-hydroxylase-C-17,20-lyase): Potential agents for the treatment of prostatic cancer", Journal of Medicinal Chemistry, American Chemical Society, US, US , (19950101), vol. 38, no. 13, doi:10.1021/jm00013a022, ISSN 0022-2623, pages 2463 - 2471, XP002302489 |
| OPPOSITION | - Mulholland D J, Dedhar S, Wu H, Nelson C C, "PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer", Oncogene, Nature Publishing Group UK, London, London , (20060101), vol. 25, no. 3, doi:10.1038/sj.onc.1209020, ISSN 0950-9232, pages 329 - 337, XP055892113 |
| OPPOSITION | - TANNOCK et al., "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer", The new England Journal of Medicine, (20040000), vol. 351, no. 15, pages 1502 - 1512, XP002623317 |
| OPPOSITION | - TANNOCK IAN F et al, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.", New England Journal of Medicine, The - NEJM, US , (20041007), vol. 351, no. 15, doi:10.1056/NEJMoa040720, ISSN 1533-4406, pages 1502 - 1512, XP002623317 |
| OPPOSITION | - TANNOCK IAN F et al, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.", New England Journal of Medicine, US , (20041007), vol. 351, no. 15, doi:10.1056/NEJMoa040720, ISSN 1533-4406, pages 1502 - 1512, XP002623317 |
| OPPOSITION | - TANNOCK IAN F; WIT DE RONALD; BERRY WILLIAM R; ET AL, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer", N Engl J Med, (20041007), vol. 351, no. 15, pages 1502 - 1512, XP002623317 |
| OPPOSITION | - TANNOCK IAN F , WIT DE RONALD, BERRY WILLIAM R, ET AL, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.", New England Journal of Medicine, US , (20041007), vol. 351, no. 15, doi:10.1056/NEJMoa040720, ISSN 1533-4406, pages 1502 - 1512, XP002623317 |
| OPPOSITION | - ATTARD G et al, "Abiraterone, an oral, irreversible CYP450C17 enzyme inhibitor appears to have activity in post-docetaxel castration refractory prostate cancer (CRPC) patients (pts)", Annals of Oncology, NL , (20070701), vol. 18, no. Suppl.9, doi:10.1093/annonc/mdm318, ISSN 0923-7534, XP002497667 |
| OPPOSITION | - ATTARD G,et al, "Abiraterone, an oral, irreversible CYP450C17 enzyme inhibitor appears to have activity in post-docetaxel castration refractory prostate cancer (CRPC) patients (pts)", Annals of Oncology, NL , (20070701), vol. 18, no. Suppl.9, doi:10.1093/annonc/mdm318, ISSN 0923-7534, XP002497667 |
| OPPOSITION | - ATTARD G; REID A; MOLIFE R; SINHA R; THOMPSON E; BARRETT M; LEE G; PARKER C; DEARNALEY D; DE BONO J S, "51PD Abitraterone, an oral, irreversible, CYP450C17 enzyme inhibitor appears to have activity in post-docetaxel castration refractory prostate cancer (CRPC) Patients (PTS)", Annals of Oncology, (20070000), vol. 18, doi:10.1093/annonc/mdm318, pages ix173 - ix174, XP002497667 |
| OPPOSITION | - ATTARD G, REID A, MOLIFE R, SINHA R, THOMPSON E, BARRETT M, LEE G, PARKER C, DEARNALEY D, DE BONO J S, "Abiraterone, an oral, irreversible CYP450C17 enzyme inhibitor appears to have activity in post-docetaxel castration refractory prostate cancer (CRPC) patients (pts)", Annals of Oncology, NL , (20070701), vol. 18, no. Suppl.9, doi:10.1093/annonc/mdm318, ISSN 0923-7534, XP002497667 |
| OPPOSITION | - SCHOLZ, M. et al., "Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone", Journal of Urology, (20050000), vol. 173, no. 6, doi:10.1097/01.ju.0000158449.83022.40, pages 1947 - 1952, XP025377674 |
| OPPOSITION | - SCHOLZ M et al., "Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone", Journal of Urology, (20050601), vol. 173, no. 6, doi:10.1097/01.ju.0000158449.83022.40, pages 1947 - 1952, XP025377674 |
| OPPOSITION | - SCHOLZ M. et al., "Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone", Journal of Urology, (20050601), vol. 173, no. 6, doi:10.1097/01.ju.0000158449.83022.40, pages 1947 - 1952, XP025377674 |
| OPPOSITION | - SCHOLZ, M. JENNRICH, R. STRUM, S. BROSMAN, S. JOHNSON, H. LAM, R., "LONG-TERM OUTCOME FOR MEN WITH ANDROGEN INDEPENDENT PROSTATE CANCER TREATED WITH KETOCONAZOLE AND HYDROCORTISONE", Journal of Urology, Lippincott Williams & Wilkins, BALTIMORE, MD, US, BALTIMORE, MD, US , (20050601), vol. 173, no. 6, doi:10.1097/01.ju.0000158449.83022.40, ISSN 0022-5347, pages 1947 - 1952, XP005375234 |
| OPPOSITION | - SCHOLZ, M. ; JENNRICH, R. ; STRUM, S. ; BROSMAN, S. ; JOHNSON, H. ; LAM, R., "LONG-TERM OUTCOME FOR MEN WITH ANDROGEN INDEPENDENT PROSTATE CANCER TREATED WITH KETOCONAZOLE AND HYDROCORTISONE", Journal of Urology, Lippincott Williams & Wilkins, BALTIMORE, MD, US, BALTIMORE, MD, US, (20050601), vol. 173, no. 6, doi:10.1097/01.ju.0000158449.83022.40, ISSN 0022-5347, pages 1947 - 1952, XP025377674 |
| OPPOSITION | - ATTARD et al., "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer", BJU International, (20050000), vol. 96, pages 1241 - 1246, XP002497670 |
| OPPOSITION | - ATTARD G; BELLDEGRUN A S; DE BONO J S, "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer", BJU International, (20050000), vol. 96, pages 1241 - 1246, XP002497670 |
| OPPOSITION | - ATTARD G, BELLDEGRUN A S, DE BONO J S, "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer", BJU International, (20050101), vol. 96, doi:10.1111/j.1464-410X.2005.05821.X, ISSN 1464-4096, pages 1241 - 1246, XP002497670 |
| OPPOSITION | - ATTARD G; BELLDEGRUN A S; DE BONO J S, "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer", BJU International, (20051200), vol. 96, no. 9, doi:10.1111/j.1464-410X.2005.05821.X, pages 1241 - 1246, XP002497670 |
| OPPOSITION | - ATTARD G, BELLDEGRUN A S, DE BONO J S, "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer", BJU International, Blackwell Science, (20050101), vol. 96, doi:10.1111/j.1464-410X.2005.05821.X, ISSN 1464-4096, pages 1241 - 1246, XP002497670 |
| OPPOSITION | - ATTARD, G. et al., "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer", British Journal of Urology, (20050000), vol. 96, doi:10.1111/j.1464-410X.2005.05821.X, pages 1241 - 1246, XP002497670 |
| OPPOSITION | - Pienta Kenneth J., Bradley Deborah, "Mechanisms underlying the development of androgen- independent prostate cancer", CLINICAL CANCER RESEARCH, (20060315), vol. 12, no. 6, pages 1665 - 1671, XP055848766 |
| OPPOSITION | - Pienta Kenneth J., Bradley Deborah, "Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer", Clinical Cancer Research, Association for Cancer Research, US, US, (20060315), vol. 12, no. 6, doi:10.1158/1078-0432.CCR-06-0067, ISSN 1078-0432, pages 1665 - 1671, XP055848766 |
| OPPOSITION | - Attard Gerhardt, Et Al, "Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20081001), vol. 26, no. 28, doi:10.1200/JCO.2007.15.9749, ISSN 0732-183X, pages 4563 - 4571, XP055837576 |
| OPPOSITION | - ATTARD G et al., "Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven", J Clin Oncol, (20081001), vol. 26, no. 28, pages 4563 - 71, XP55837576 |
| OPPOSITION | - Daniel C Danila; Morris Michael J; De Bono Johann S; Ryan Charles J; Denmeade Samuel R; Smith Matthew R; Taplin Mary-Ellen; Bubley Glenn J; Kheoh Thian; Haqq Christopher; Molina Arturo; Anand Aseem; Koscuiszka Michael; Larson Steve M; Schwartz Lawrence H; Fleisher Martin; Scher Howard I, "Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel- treated castration-resistant prostate cancer", Journal of Clinical Oncology,, (20100320), vol. 28, no. 9, doi:10.1200/JCO.2009.25.9259, pages 1496 - 1501, XP055750660 |
| OPPOSITION | - Daniel C. Danila, Morris Michael J., De Bono Johann S., Ryan Charles J., Denmeade Samuel R., Smith Matthew R., Taplin Mary-Ellen, Bubley Glenn J., Kheoh Thian, Haqq Christopher, Molina Arturo, Anand Aseem, Koscuiszka Michael, Larson Steve M., Schwartz Lawrence H., Fleisher Martin, Scher Howard I., "Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20100320), vol. 28, no. 9, doi:10.1200/JCO.2009.25.9259, ISSN 0732-183X, pages 1496 - 1501, XP055750660 |
| OPPOSITION | - Daniel C Danila; Morris Michael J; De Bono Johann S; Ryan Charles J; Denmeade Samuel R; Smith Matthew R; Taplin Mary-Ellen; Bubley Glenn J; Kheoh Thian; Haqq Christopher; Molina Arturo; Anand Aseem; Koscuiszka Michael; Larson Steve M; Schwartz Lawrence H; Fleisher Martin; Scher Howard I, "Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, (20100320), vol. 28, no. 9, ISSN 1527-7755, pages 1496 - 1501, XP055750660 |
| OPPOSITION | - Daniel C. Danila, Morris Michael J., De Bono Johann S., Ryan Charles J., Denmeade Samuel R., Smith Matthew R., Taplin Mary-Ellen, Bubley Glenn J., Kheoh Thian, Haqq Christopher, Molina Arturo, Anand Aseem, Koscuiszka Michael, Larson Steve M., Schwartz Lawrence H., Fleisher Martin, Scher Howard I., "Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer", Journal of Clinical Oncology, US , (20100320), vol. 28, no. 9, doi:10.1200/JCO.2009.25.9259, ISSN 0732-183X, pages 1496 - 1501, XP055750660 |
| OPPOSITION | - DANILA D C et al., "Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer", Journal of Clinical Oncology, (20100000), vol. 28, no. 9, doi:10.1200/JCO.2009.25.9259, pages 1496 - 1501, XP055750660 |
| OPPOSITION | - DANILA D. C. et al., "Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer", Journal of Clinical Oncology, (20100000), vol. 28, no. 9, doi:10.1200/JCO.2009.25.9259, pages 1496 - 1501, XP055750660 |
| OPPOSITION | - DANILA, D.C. et al., "Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer", Journal of Clinical Oncology, (20100000), vol. 28, no. 9, doi:10.1200/JCO.2009.25.9259, pages 1496 - 1501, XP055750660 |
| OPPOSITION | - DANILA DC et al., "Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer", Journal of Clinical Oncology, (20100320), doi:10.1200/JCO.2009.25.9259, pages 1496 - 1501, XP055750660 |
| OPPOSITION | - DE COSTER, R. et al., "Effects of high-dose ketoconazole and dexamethasone on ACTH- stimulated adrenal steroidogenesis in orchiectomized prostate cancer patients", Acta Endocrinologica (Copenh, (19870000), vol. 115, doi:10.1530/acta.0.1150265, pages 265 - 271, XP008153090 |
| OPPOSITION | - DE COSTER R et al., Effects of high-dose ketoconazole and dexamethasone on ACTH- stimulated adrenal steroidogenesis in orchiectomized prostate cancer patients, vol. 115, no. 2, pages 265 - 271, XP008153090 |
| OPPOSITION | - DE COSTER R et al, "EFFECTS OF HIGH-DOSE KETOCONAZOLE AND DEXAMETHASONE ON ACTH-STIMULATED ADRENAL STEROIDOGENESIS IN ORCHIECTOMIZED PROSTATIC CANCER PATIENTS", ACTA ENDOCRINOLOGICA., SCANDINAVIAN UNIVERSITY PRESS, OSLO., SE, SE, (19870101), vol. 115, no. 2, doi:10.1530/acta.0.1150265, ISSN 0001-5598, pages 265 - 271, XP008153090 |
| OPPOSITION | - DE COSTER R; MAHLER C; DENIS L; COENE M C; CAERS I; AMERY W; HAELTERMAN C; BEERENS D, "EFFECTS OF HIGH-DOSE KETOCONAZOLE AND DEXAMETHASONE ON ACTH-STIMULATED ADRENAL STEROIDOGENESIS IN ORCHIECTOMIZED PROSTATIC CANCER PATIENTS", ACTA ENDOCRINOLOGICA., SCANDINAVIAN UNIVERSITY PRESS, OSLO., SE, SE , (19870101), vol. 115, no. 2, doi:10.1530/acta.0.1150265, ISSN 0001-5598, pages 265 - 271, XP008153090 |
| OPPOSITION | - Nakamura Yasuhiro, Suzuki Takashi, Nakabayashi Masao, Endoh Mareyuki, Sakamoto Kazuhiro, Mikami Yoshiki, Moriya Takuya, Ito Akihiro, Takahashi Shoki, Yamada Shogo, Arai Yoichi, Sasano Hironobu, "In situ androgen producing enzymes in human prostate cancer", Endocrine Related Cancer, BioScientifica Ltd., GB, GB , (20050301), vol. 12, no. 1, doi:10.1677/erc.1.00914, ISSN 1351-0088, pages 101 - 107, XP055892122 |
| OTHER | - A. O'DONNELL et al., "Hormonal impact of the 17[alpha]-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer", British Journal of Cancer, (20040614), vol. 90, no. 12, pages 2317 - 2325, XP002464868 |
| OTHER | - A. O'DONNELL ET AL, "Hormonal impact of the 17[alpha]-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer", BRITISH JOURNAL OF CANCER, (20040614), vol. 90, no. 12, pages 2317 - 2325, XP002464868 |
| OTHER | - Camille Motta et al, "Androgen deprivation therapy: the future", Camille Motta et al, Roger S Kirby et al, Prostate Cancer, Principles and Practice, Taylor & Francis Group, (20060100), pages 915 - 928, XP055458243 |
| OTHER | - "Chapter 93 - Androgen deprivation therapy: the future", Kirby et al., Prostate Cancer, Principles and Practice, (2006), pages 915 - 928, XP055752081 |
| OTHER | - EMA, "Zytiga 250 mg tablets", EMA - Summary of Product Characteristics, (20140121), pages 1 - 77, URL: https://www.medicines.org.uk/, XP055750684 |
| OTHER | - EMEA, "Assessment Report For Zytiga (abiraterone)", European Medicines Agency - Procedure No. EMEA/H/C/002321, (20110721), pages 1 - 78, URL: https://www.ema.europa.eu/en/documents/assessment-report/zytiga-epar-public-assessment-report_en.pdf, XP055750690 |
| OTHER | - GLENN S. GERBER et al, "PROSTATE SPECIFIC ANTIGEN FOR ASSESSING RESPONSE TO KETOCONAZOLE AND PREDNISONE IN PATIENTS WITH", The Journal of Urology, (1990101), vol. 144, no. 5, pages 1177 - 1179, XP008151701 |
| OTHER | - GOLDSMITH et al., "Hypogonadism and mineralocorticoid excess. The 17-hydroxylase deficiency syndrome", N Engl J Med, (19670928), vol. 277, no. 13, pages 673 - 677, XP055750805 |
| OTHER | - P. EMGARD et al., "External otitis caused by infection with Pseudomonas aeruginosa or Candida albicans cured by use of a topical group III steroid, without any antibiotics", Acta Oto-Largyngologica, (20050400), vol. 125, no. 4, pages 346 - 352 |
| OTHER | - R. J. AUCHUS, "The genetics, pathophysiology, and management of human deficiencies of P450c17", Endocrinology and Metabolism Clinics of North America, (20010300), vol. 30, no. 1, pages 101 - 119 |
| OTHER | - R. P. RUTZ, "Effects of corticosteroid use on treatment of solid tumours", The Lancet, (20021214), vol. 360, no. 9349, pages 1969 - 1970, XP04795228 |
| OTHER | - "Zytiga 250 mg tablets", (20140121), XP055750684 |
| OTHER | - J. S. LAM et al., "Secondary Hormonal Therapy for Advanced Prostate Cancer", The Journal of Urology, (20060100), vol. 175, no. 1, pages 27 - 34, XP024990140 |
| OTHER | - M. FAKIH et al., "Glucocorticoids and treatment of prostate cancer: A preclinical and clinical review", Urology, (20021001), vol. 60, no. 4, pages 553 - 561, XP002495992 |
| OTHER | - Oliver Sartor et al, "Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer", Urology, (199808), vol. 52, no. 2, pages 252 - 256, XP055797370 |
| OTHER | - I. HERR, J. PFITZENMAIER, "Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases", The Lancet Oncology, (20060501), vol. 7, no. 5, pages 425 - 430, XP028057866 |
| OTHER | - ATTARD et al., "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer", BJU International, (20050000), vol. 96, pages 1241 - 1246, XP002497670 |
| OTHER | - DANILA D C et al., "Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer", Journal of Clinical Oncology, (20100320), vol. 28, no. 9, pages 1496 - 1501, XP055750660 |
| SEARCH | - GERBER G S ET AL, "Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, (19900101), vol. 144, no. 5, ISSN 0022-5347, pages 1177 - 1179, XP008151701 [Y] 1-15 * abstract * * page 1177, column l, paragraph 1 - column r, paragraph 1 * * page 1179, column l, paragraph 5 - column r, paragraph 2 * |
| SEARCH | - MADAN RAVI A ET AL, "Abiraterone Cougar Biotechnology", IDRUGS, CURRENT DRUGS LTD, GB, (200601), vol. 9, no. 1, ISSN 1369-7056, pages 49 - 55, XP008087480 [Y] 1-15 * the whole document * |
| SEARCH | - O'DONNELL A ET AL, "Hormonal impact of the 17[alpha]-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer", BRITISH JOURNAL OF CANCER 14 JUN 2004 UNITED KINGDOM, (20040614), vol. 90, no. 12, ISSN 0007-0920, pages 2317 - 2325, XP002464868 [X] 1,2,4,9,10,12-15 * page 2318, column R, paragraph 1 * * page 2319, column L, paragraph 7 - column R, paragraph 13 * * page 2320, column R, paragraph 2 * * page 2323, column R, paragraph 4 * |
| SEARCH | - SCHOLZ M ET AL, "LONG-TERM OUTCOME FOR MEN WITH ANDROGEN INDEPENDENT PROSTATE CANCER TREATED WITH KETOCONAZOLE AND HYDROCORTISONE", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 173, no. 6, ISSN 0022-5347, (20050601), pages 1947 - 1952, (20050601), XP027855453 [Y] 1-15 * abstract * * page 1947, column l, paragraph 1 * * page 1947, column r, paragraph 2 * * page 1950, column r, paragraph 2 - page 1951, column r, paragraph l * |
| SEARCH | - FOSSA ET AL, "Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study", EUROPEAN UROLOGY, ELSEVIER BV, NL, (20071121), vol. 52, no. 6, doi:10.1016/J.EURURO.2007.01.104, ISSN 0302-2838, pages 1691 - 1699, XP022356374 [YP] 1-15 * abstract * |
| SEARCH | - HARRIS ET AL, "Low Dose Ketoconazole With Replacement Doses of Hydrocortisone in Patients With Progressive Androgen Independent Prostate Cancer", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, (20020801), vol. 168, no. 2, doi:10.1016/S0022-5347(05)64675-7, ISSN 0022-5347, pages 542 - 545, XP005540121 [Y] 1-15 * abstract * * page 542, column l, paragraph 1 - page 543, column l, paragraph 2 * * page 544, column r, paragraph 2 - page 545, column l, paragraph l * |
| SEARCH | - DE COSTER R ET AL, "EFFECTS OF HIGH-DOSE KETOCONAZOLE AND DEXAMETHASONE ON ACTH-STIMULATED ADRENAL STEROIDOGENESIS IN ORCHIECTOMIZED PROSTATIC CANCER PATIENTS", ACTA ENDOCRINOLOGICA, (1987), vol. 115, no. 2, ISSN 0001-5598, pages 265 - 271, XP008153090 [Y] 1-15 * abstract * * page 265, column r, paragraph 1 - page 266, column l, paragraph 5 * * page 270 * |
